VARI-SU2C
15 results.
A first-of-its-kind combination of medications may enable the immune system to better combat lung cancer, which claims more lives than any other cancer type and…
International collaboration pairs immunotherapy with an epigenetic drug to stop progression of chronic myelomonocytic leukemia and myelodysplastic syndrome into acute myeloid leukemia GRAND RAPIDS, Mich.…
Safety and efficacy of combining talazoparib with decitabine to treat acute myeloid leukemia (AML) are subject of multi-site clinical trial GRAND RAPIDS, Mich. (March 7,…
When it comes to biomedical research and science education, a year can make all the difference. In 2016, we celebrated Van Andel…
GRAND RAPIDS, Mich. (Jan. 28, 2016)—The first clinical trial to move forward as part of the Van Andel Research Institute–
GRAND RAPIDS, Mich. (Feb. 26, 2015)—Renowned cancer scientist and epigenetics expert Stephen Baylin, M.D., has accepted an appointment at Van Andel Research Institute (VARI) to help…
Grand Rapids, Michigan (October 20, 2014)— The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus…